Jessica Yan

Core Clinical Faculty, Hematology and Medical Oncology, Olive View-UCLA Medical Center

Specialty: Hematology and Medical Oncology

Background: Dr. Jessica Yan is a board-certified hematologist and oncologist who the treats all patients with benign and malignant hematologic conditions as well as solid tumors. She has a particular interest in cutaneous, breast and thoracic oncology, quality improvement and providing comprehensive cancer care to patients who face significant barriers to accessing quality
healthcare.

Dr. Yan received her B.S. in psychobiology from University of California, Los Angeles and her M.D. from St. George’s University in Grenada, West Indies. She subsequently completed her Internal Medicine residency and Chief Residency at the University of Arizona in Tucson. This was followed by Hematology-Oncology fellowship training at Harbor-UCLA in Torrance. She joined Kaiser South Bay from 2019 to 2024 to enhance her clinical skills in an innovative healthcare setting and returned to the Los Angeles County system in 2024. She hopes to bring her clinical experience to the Olive View to enhance the quality of care for the underserved community.

Research Interests:
Quality improvement

Education:
B.S. University of California, Los Angeles 2007 M.D. Saint George’s University 2012 Internal Medicine Residency, University of Arizona 2012-2015 Chief Resident Internal Medicine, University of Arizona, 2015-2016 Hematology and Medical Oncology Fellowship, Harbor-UCLA Medical Center, 2016-2019

Recent Publications + Projects:
Yan, J., Pan, K. Germline mutation testing among women with breast cancer in the safety net setting. Poster presentation. San Antonio Breast Cancer Symposium2018

Gong, J., Yan, J., Forscher, C., Hendifar, A. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Design, Development and Therapy. April 2018. PMID 29670334 Puvvada, S., Guillen-Rodriguez J, Yan J, Inclan L, Heard K, Rivera XI, Anwer F, Mahadevan D, Schatz JH, Persky DO. Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after Cytoreductive ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final results of a Phase II Study. Oncology. February 2018. PMID 29471300

Bilal, J., Yan, J., Pandey, A. Hematologic, dermatologic and respiratory toxicities of Portland
Cement. American Journal of the Medical Sciences. May 2016. PMID 27140716

Yan, J., Walker, C., Chalasani, P. Spontaneous Paraesophageal Hematoma in Hemophilia B.
American College of Gastroenterology Case Reports Journal. October 2015. PMID 26504872

Interests:
Spending time with family, exercising, discovering new podcasts, and finding good eats in Los
Angeles